Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETRAP: SR-fampridine + Resistance Training in MS
NCT02143167Phase 4Completed
- Sponsor
- University of Southern Denmark
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by University of Southern Denmark. Primary endpoint: Muscle power in the lower limbs at 14 weeks. Started May 2014; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02143167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143167.